Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Triplet Platinum-based Combination Sequential Chemotherapy Improves Survival Outcome and Quality of Life of Advanced Non-small Cell Lung Cancer Patients

  • Chen, Li-Kun (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) ;
  • Liang, Ying (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) ;
  • Yang, Qun-Ying (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) ;
  • Xu, Fei (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) ;
  • Zhou, Ning-Ning (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) ;
  • Xu, Guang-Chuan (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) ;
  • Liu, Guo-Zhen (Department of Radiation Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) ;
  • Wei, Wei-Dong (Department of Thoracic Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Maintenance chemotherapy is one strategy pursued in recent years with intent to break through the chemotherapy plateau for advanced non-small cell lung cancer (NSCLC). However, given the toxicity, platinum-based combinations are rarely given for this purpose. We carried out the present prospective study of triplet platinum-based combination sequential chemotherapy in advanced NSCLC to investigate if patients could tolerate and benefit from such intensive treatment. Methods: From Dec 2003 to Dec 2007, 190 stage IIIB and IV NSCLC patients in Sun yat-sen University sequentially received the 3 platinum-based combination (TP-NP-GP) treatment (T: paclitaxol175$mg/m^2$ d1; N: vinorelbine25$mg/m^2$ d1 and 8; G: gemcitabine1$g/m^2$ d1 and 8; P: cisplatin20$mg/m^2$ d1-5; repeated every 3 weeks). Patients were followed up to at least 3 years to obtain survival data. Treatment toxicities and the quality of life (QOL) were assessed during the whole treatment. Results: There were 187 patients evaluable. The TP, NP and GP response rates with sequential use were 42.8% (80/187), 41.1% (65/158) and 28.8% (21/73) respectively. Median survival time was 18.2 months and the 1, 2 and 3 year overall survival (OS) rates were 78.7%, 38.5% and 21.3%. Patients receiving > 6 cycles of chemotherapy had significantly longer OS and TTP (MST 25.3 vs. 14.5 months, TTP 15.1 vs. 9.1 months). The QOL on the whole for the patients was improved after chemotherapy. Conclusions: The sequential chemotherapy strategy with triplet platinum-based combination regimens can improve the survival outcome and the quality of life of advanced non-small cell lung cancer patients.

Keywords

References

  1. Belani CP, Barstis J, Perry MC, et al (2003). Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol, 21, 2933-9. https://doi.org/10.1200/JCO.2003.02.563
  2. Belani CP, Pereira JR, von Pawel J, et al (2006). Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer, 53, 231-9. https://doi.org/10.1016/j.lungcan.2006.05.003
  3. Brodowicz T, Krzakowski M, Zwitter M, et al (2006). Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer, 52, 55-63.
  4. Cappuzzo F, Ciuleanu L, Stelmakh S, et al (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised,placebo-controlled phase 3 study. Lancet Oncol, 11, 521-9. https://doi.org/10.1016/S1470-2045(10)70112-1
  5. Cella DF, Tulsky DS, Gray G, et al (1993). The functional assessment of cancer therapy scale. Development and validation of the general measure. J Clin Oncol, 11, 570-9. https://doi.org/10.1200/JCO.1993.11.3.570
  6. Chiappori A, Simon G, Williams C, et al (2005). Phase II study of first-line sequential chemotherapy with gemcitabinecarboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology, 68, 382-90. https://doi.org/10.1159/000086979
  7. Ciuleanu T, Brodowicz T, Zielinski C, et al (2007). Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet, 374, 1432-40.
  8. Edelman MJ, Clark JI, Chansky K, et al (2004). Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): Carboplatin/ gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res, 10, 5022-6. https://doi.org/10.1158/1078-0432.CCR-04-0002
  9. Fidias PM, Dakhil SR, Lyss AP, et al (2009). Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced nonsmall- cell lung cancer. J Clin Oncol, 27, 591-8. https://doi.org/10.1200/JCO.2008.17.1405
  10. Fisher MD, D'Orazio A (2000). Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clin Lung Cancer, 2, 21-2. https://doi.org/10.1016/S1525-7304(11)70620-9
  11. Grossi F, Aita M, Follador A, et al (2007). Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist, 12, 451-64. https://doi.org/10.1634/theoncologist.12-4-451
  12. Grossi F, Belvedere O, Fasola G, et al (2004). Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced onsmall cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer, 46, 99-106. https://doi.org/10.1016/j.lungcan.2004.03.003
  13. Hosoe S, Komuta K, Shibata K, et al (2003). Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02). Br J Cancer, 88, 342-7. https://doi.org/10.1038/sj.bjc.6600723
  14. Non-small Cell Lung Cancer Collaborative Group (1995). Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomized clinical trials. BMJ, 311, 899-90. https://doi.org/10.1136/bmj.311.7010.899
  15. Pallis A, Agelidou A, Papakotoulas P, et al (2006). A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer, 52, 165-71. https://doi.org/10.1016/j.lungcan.2006.01.005
  16. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  17. Smith IE, O'Brien ME, Talbot DC, et al (2001). Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol, 19, 1336-43. https://doi.org/10.1200/JCO.2001.19.5.1336
  18. Socinski MA, Schell MJ, Peterman A, et al (2002). Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol, 20, 1335-43. https://doi.org/10.1200/JCO.20.5.1335
  19. Westeel V, Quoix E, Moro-Sibilot D, et al (2005). Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst, 97, 499-506. https://doi.org/10.1093/jnci/dji096

Cited by

  1. Phase II Study on Dose Escalating Schedule of Paclitaxel Concurrent with Radiotherapy in Treating Patients with Locally Advanced Non-small Cell Lung Cancer vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1699
  2. Clinical Efficacy of Bevacizumab Concomitant with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3447
  3. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen vol.36, pp.12, 2015, https://doi.org/10.1007/s13277-015-3672-z
  4. Changes to and Determinants of Quality of Life in Patients With Advanced Non-Small-Cell Lung Cancer Undergoing Initial Chemotherapy pp.1682-3141, 2017, https://doi.org/10.1097/jnr.0000000000000148
  5. microRNA-664 enhances proliferation, migration and invasion of lung cancer cells vol.13, pp.6, 2017, https://doi.org/10.3892/etm.2017.4433
  6. The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro vol.40, pp.1, 2017, https://doi.org/10.3892/ijmm.2017.2989
  7. Op18/Stathmin Is Involved in the Resistance of Taxol Among Different Epithelial Carcinoma Cell Lines vol.29, pp.9, 2014, https://doi.org/10.1089/cbr.2014.1649